SNOMED CT Concept  138875005

Pharmaceutical / biologic product  373873005

Medicinal product  763158003

Product manufactured as oral dose form  440131009

Ribavirin-containing product in oral dose form  430152003

Ribavirin+interferon alpha-2b   410841001

SNOMED CT code


SNOMED code410841001
nameRibavirin+interferon alpha-2b
statusremoved
date introduced2004-07-31
date removed2018-07-31
fully specified name(s)Ribavirin+interferon alpha-2b (product)
synonymsRibavirin+interferon alpha-2b
parentsRibavirin-containing product in oral dose form   430152003
hierarchies
a selection of possible paths
SNOMED CT Concept   138875005
  Pharmaceutical / biologic product   373873005
    Medicinal product   763158003
      Product manufactured as oral dose form   440131009
        Ribavirin-containing product in oral dose form   430152003
          Ribavirin+interferon alpha-2b   410841001  removed: 2018-07-31

ancestors
sorted most to least specific
  • Ribavirin-containing product in oral dose form   430152003
  • Ribavirin-containing product   35063004
  • Product manufactured as oral dose form   440131009
  • Azole-containing product   764881006
  • Medicinal product categorized by disposition   766779001
  • Antiviral agent   788081006
  • Nitrogen and/or nitrogen compound-containing product   768700009
  • Medicinal product categorized by therapeutic role   763087004
  • Medicinal product categorized by structure   763760008
  • Medicinal product   763158003
  • Pharmaceutical / biologic product   373873005
  • SNOMED CT Concept   138875005
cpt crosswalks

Rules-based maps relating CPT® codes to and from SNOMED CT® clinical concepts.  Forward and backward mapping allows for easy transition between code sets. Map-A-Code crosswalk tool easily crosswalks multiple codes between the code sets.

Access to this feature is available in the following products:
  • CPT® to SNOMED Crosswalks

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.